Yousef, A.; Wang, N.; Yousef, M.; Elfert, K.; Telbany, A.; Vaghefi, A.; Nguyen, K.; Ripley, K.; Rieth, K.; Peverini, D.;
et al. Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth. J. Clin. Med. 2026, 15, 4449.
https://doi.org/10.3390/jcm15124449
AMA Style
Yousef A, Wang N, Yousef M, Elfert K, Telbany A, Vaghefi A, Nguyen K, Ripley K, Rieth K, Peverini D,
et al. Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth. Journal of Clinical Medicine. 2026; 15(12):4449.
https://doi.org/10.3390/jcm15124449
Chicago/Turabian Style
Yousef, Abdelrahman, Niven Wang, Mahmoud Yousef, Khaled Elfert, Ahmed Telbany, Arman Vaghefi, Kevin Nguyen, Katherine Ripley, Kara Rieth, Daniel Peverini,
and et al. 2026. "Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth" Journal of Clinical Medicine 15, no. 12: 4449.
https://doi.org/10.3390/jcm15124449
APA Style
Yousef, A., Wang, N., Yousef, M., Elfert, K., Telbany, A., Vaghefi, A., Nguyen, K., Ripley, K., Rieth, K., Peverini, D., Zeineddine, F., Gundlapalli, H. K., Kondubhatla, K., Sheikh, A. B., Kaza, A., Castillo, E. F., Chang, C., & Birg, A.
(2026). Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth. Journal of Clinical Medicine, 15(12), 4449.
https://doi.org/10.3390/jcm15124449
